Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed solid tumor or lymphoma that is refractory to currently available standard therapies or for which there are no curative therapies
• No known brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• More than 12 weeks
• Hematopoietic
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• No prior bleeding disorder
• Hepatic
• Bilirubin normal
• AST/ALT no greater than 2.5 times upper limit of normal
• INR/PTT normal
• Renal
• Creatinine normal OR
• Creatinine clearance at least 60 mL/min
• Cardiovascular
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 6 months after study participation
• HIV negative
• T4 or thyroid stimulating hormone normal
• No thyroid disease
• No prior allergic reactions attributed to compounds of similar chemical or biologic composition to study drug (e.g., rituximab or immunoglobulin G)
• No ongoing or active infection
• No other uncontrolled concurrent illness that would preclude study participation
• No psychiatric illness or social situation that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Endocrine therapy
• Not specified
• Radiotherapy
• More than 4 weeks since prior radiotherapy and recovered
• Surgery
• More than 4 weeks since prior surgery
• Other
• No other concurrent investigational agents
• No other concurrent anticancer agents or therapies (commercial or investigational)